Brief: Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
25/09/2024 13:04
Sept 25 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS COMPLETES TARGET ENROLLMENT IN
PIVOTAL
ADVANCE-HTN TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF
HYPERTENSION
* MINERALYS THERAPEUTICS INC - EXPECTS TO ANNOUNCE TOPLINE
DATA IN
Q1 2025
Source text for Eikon: ID:nGNX8HZty2
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway